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patients undergoing CPR and by those left untreated through spent opportunity costs. 
This serves as a reminder that the technological imperative – because existing technol-
ogy means that something can be done, then this action ought to be done – must be 
thoughtfully considered by those undertaking health technology assessments.
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OBJECTIVES: Utilize simple measures, such as mortality and hospital volume, to 
create and validate the composite quality score. Although payers are increasingly 
reporting information on hospital volume and mortality to rank hospitals, the value
of these data is uncertain. There is a need for better quality measures. METHODS:
We used Medicare Analysis Provider and Review ﬁ les for resection of pancreatic cancer
(2003–06). Using the empirical Bayes approach to combine mortality rates with
information on hospital volume at each hospital, we created an index to weight 
observed mortality according to how reliable it is estimated, with the remaining weight 
placed on hospital volume. We validated our index by a) establishing the extent to 
which it explained hospital-level variation in risk adjusted mortality rates, and b) 
determining how well it predicted future hospital performance. RESULTS: Since the 
average hospital caseload was only 6, 16% of the weight was placed on mortality and 
84% on volume. Composite measure explained the highest percentage of hospital level 
variation (54%) and predicted the largest differences in future risk adjusted mortality
across hospitals (odd ratio  3.16, p  0.000). CONCLUSIONS: Using national 
Medicare data for resection of pancreatic cancer, we found that simple composite
measure was a strong predictor of subsequent performance of the operation. In this
regard, it was more effective than individual measures. Such measures would be useful 
to help patients and payers identify low quality hospitals for major surgery.
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OBJECTIVES: Administrative data are often used to identify patients for inclusion 
in quality performance measures. We examined the speciﬁ city of ICD-9 codes from
administrative data for identifying patients hospitalized for heart failure (HF).
METHODS: Charts of 90 adults (q25 years) admitted to two university hospitals
between November 2005 and October 2006 were selected on the basis of ICD-9
discharge diagnosis [primary diagnosis of HF (n  45), or without HF (n  45)]. 
The ICD-9 codes used to identify HF were those used in the Joint Commission 
National Hospital Quality Measures. Medical charts were abstracted to identify 
the physician discharge diagnoses. Speciﬁ city was calculated by comparing the
number of patients identiﬁ ed with HF via ICD-9 codes from administrative data to 
the number identiﬁ ed by medical record review [(true negatives/(true negatives 
false positives)]. The main analysis was based on the reference standard being the
physician primary discharge diagnosis of HF. In sensitivity analyses we expanded the 
deﬁ nition of the reference standard to include; A) physician secondary discharge
diagnosis of HF with shortness of breath (SOB) or respiratory failure (RF) as the 
primary diagnosis; and B) physician secondary discharge diagnosis of HF with SOB,
RF, arrhythmia, or valvular disease as the primary diagnosis. RESULTS: The speciﬁ city
of the administrative data was 75.0% (95% CI 62.1–85.3%) for the main analysis. 
Using the expanded deﬁ nitions of the reference standard A and B above, the speciﬁ city 
was 77.6 % (95% CI 64.7–87.5 %) and 81.8% (95% CI 69.1–90.9%), respectively. 
CONCLUSIONS: Administrative data have relatively high speciﬁ city (75%) for
identifying hospitalized patients with heart failure. Additional analyses are needed to
determine the extent to which quality among those captured by administrative data
reﬂ ects overall quality, and to determine the sensitivity of administrative data for 
identifying HF patients.
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OBJECTIVES: The objective of this study was to determine the likelihood of receiving 
renin system agents as the ﬁ rst HTN treatment among patients with prior renal 
disease. METHODS: This retrospective study utilized data from the Henry Ford 
Health System to identify HTN patients with renal disease who received a renin system 
agent at any time. Patients were 18 years old with a minimum of one year enrollment 
in the health plan of one year following the ﬁ rst HTN visit in the study period. The
ﬁ rst HTN treatment was characterized as monotherapy or combination therapy with
renin system agents. Logistic regression modeling determined the likelihood of receiv-
ing a renin system agent ﬁ rst line among patients diagnosed with renal disease before 
initiating HTN therapy compared to patients diagnosed with renal disease after initiat-
ing HTN therapy while adjusting for covariates. RESULTS: A total of 4,523 patients
had a diagnosis of HTN and renal disease (mean age 64 years, 50% white and 54% 
male). Approximately 58% of patients were treated with two HTN agents and 42% 
with three or more. Only 338 (7.5%) patients were diagnosed with renal disease before 
their HTN treatment. Slightly higher proportions of patients diagnosed with renal 
disease before, compared to after initiating HTN therapy (59% vs. 51% respectively),
were prescribed renin system agents ﬁ rst line. After adjusting for covariates, patients 
diagnosed with renal disease before initiating HTN therapy were not more likely to 
receive a renin system agent ﬁ rst-line compared to patients diagnosed with renal 
disease after initiating HTN therapy (OR: 0.863, 95% CI: 0.664–1.123). CONCLU-
SIONS: While all patients received renin system agents, those with prior renal disease 
were not more likely to receive this treatment ﬁ rst line suggesting an opportunity to
optimize treatment for renal patients with medications that block the Renin-Angio-
tensin-Aldosterone System.
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OBJECTIVES: To compare dose-equivalence, adherence and subsequent switch
rates among patients recently switched from a branded to generic version of the 
same statin (generic substitution, GS) vs. those switched from branded statin to 
generic version of a different statin (therapeutic substitution, TS). METHODS: In a 
retrospective cohort analysis among adult enrollees in ^90 US health plans, we identi-
ﬁ ed adult patients who switched from a branded to generic statin from July-December
2006. Patients were classiﬁ ed by type of statin switch: GS (eg, branded simvastatin 
nú generic simvastatin), and TS (eg, branded atorvastatin nú simvastatin). Demo-
graphic and clinical data were collected from claims before switch through six
months follow-up. Outcomes of interest included proportion of patients that
switched to a less potent daily dose, that switched back to the previous branded 
statin after switch, and that were at least 80% adherent during the 6 months after
initial switch. Signiﬁ cant predictors of each clinical outcome were identiﬁ ed using 
multivariable logistic regression models, adjusting for differences between groups in 
covariates and potential confounders. RESULTS: The TS (n  3,807) and GS (n 
40,165) groups were generally similar demographically, although TS was more fre-
quent in HMO health plans than GS (40.6% vs. 33.7%, p  .001), and less likely in 
POS plan patients (9.2% vs. 16.6%). Compared to GS, TS patients were more likely
to be switched to a less potent dose (26.2 % vs. 0.5%); less likely to be adherent 
(70.2% vs. 79.5%); and more likely to switch back to the previous branded statin 
(11.3% vs. 2.9%, p  .001 for all). These effects remained signiﬁ cant in the regression 
models adjusting for demographic and baseline clinical characteristics. CONCLU-
SIONS: TS is more likely to involve a subsequent disruption to statin therapy than
GS. TS could potentially lead to adverse impacts on patients’ outcomes, and should 
be studied further.
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OBJECTIVES: Under estimating CV risk levels of patients may lead to inappropriate 
care and unintended clinical and economic consequences. It is not known to what
extent Canadian physicians correctly identify the CV risk level of patients who have
had previous CV events and/or a diagnosis of diabetes mellitus. METHODS: A total 
of 431 General Practioners from across Canada collected pre-speciﬁ ed data on a case 
record form (CRF) for CV patients during routine ofﬁ ce visits between June 2007 and 
December 2007. Physicians were asked to assess the risk level of each patient during
the completion of the CRF. Patients for whom the physician reported a diagnosis of 
diabetes mellitus (DM) and/or who had a previous history of myocardial infarction 
(MI), stroke (S), or peripheral artery disease (PAD) were extracted. Physician assessed 
risk levels were then compared to this subset of commonly accepted high-risk patients.
RESULTS: Data on 14,982 patients was obtained. A total of 2822 had a previous 
history of MI, S, or PAD. Physicians correctly assessed 2540 (90.0%) as high risk, 
however differences were observed between provinces: BC 81.5%, AB 86.9%, QC 
92.9%, ON 90.3%, NS 90.9%, NB 85.3%. A further 1850 had DM and a previous
history of MI, S, or PAD. Physicians correctly assessed 1778 (96.1%) as high risk, 
however regional differences were observed: BC 87.5%, AB 89.6%, QC 98.5%, ON
97.0%, NS 94.4%, NB 97.7%. CONCLUSIONS: Despite agreement that patients 
with a previous history of MI, S, or PAD should be viewed as high risk, and that those 
with DM and a previous history of MI, S, or PAD are high risk, some physicians still
under estimate the CV risk. The reasons for this under assessment and the unintended
clinical and economic consequence need to be explored further.
